摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

6-[[4-[[6-(2,2,2-trifluoroethyl)thieno[2,3-d]pyrimidin-4-yl]amino]piperidin-1-yl]methyl]-3,4-dihydro-1H-quinolin-2-one

中文名称
——
中文别名
——
英文名称
6-[[4-[[6-(2,2,2-trifluoroethyl)thieno[2,3-d]pyrimidin-4-yl]amino]piperidin-1-yl]methyl]-3,4-dihydro-1H-quinolin-2-one
英文别名
——
6-[[4-[[6-(2,2,2-trifluoroethyl)thieno[2,3-d]pyrimidin-4-yl]amino]piperidin-1-yl]methyl]-3,4-dihydro-1H-quinolin-2-one化学式
CAS
——
化学式
C23H24F3N5OS
mdl
——
分子量
475.5
InChiKey
GGLLSBSAMVPWBM-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.5
  • 重原子数:
    33
  • 可旋转键数:
    5
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.43
  • 拓扑面积:
    98.4
  • 氢给体数:
    2
  • 氢受体数:
    9

文献信息

  • [EN] METHODS OF PROMOTING BETA CELL PROLIFERATION<br/>[FR] PROCÉDÉS DE PROMOTION DE LA PROLIFÉRATION DE CELLULES BÊTA
    申请人:KURA ONCOLOGY INC
    公开号:WO2018106818A1
    公开(公告)日:2018-06-14
    The present disclosure provides methods of promoting proliferation of a pancreatic cell. The methods are useful for the treatment of diabetes and other diseases characterized by impaired glucose tolerance.
    本公开提供了促进胰岛细胞增殖的方法。这些方法对于治疗糖尿病和其他以葡萄糖耐量受损为特征的疾病非常有用。
  • [EN] COMPOSITIONS COMPRISING THIENOPYRIMIDINE AND THIENOPYRIDINE COMPOUNDS AND METHODS OF USE THEREOF<br/>[FR] COMPOSITIONS COMPRENANT DES COMPOSÉS THIÉNOPYRIMIDINE ET THIÉNOPYRIDINE ET PROCÉDÉS D'UTILISATION ASSOCIÉS
    申请人:UNIV MICHIGAN
    公开号:WO2014164543A1
    公开(公告)日:2014-10-09
    The present invention relates generally to thienopyrimidine and thienopyridine class compounds and methods of use thereof. In particular embodiments, the present invention provides compositions comprising thienopyrimidine and thienopyridine class compounds and methods of use to inhibit the interaction of menin with MLL1, MLL2 and MLL-fusion oncoproteins (e.g., for the treatment of leukemia, solid cancers and other diseases dependent on activity of MLL1, MLL2, MLL fusion proteins, and/or menin).
    本发明通常涉及噻吩嘧啶和噻吩吡啶类化合物及其使用方法。在特定实施例中,本发明提供包含噻吩嘧啶和噻吩吡啶类化合物的组合物和使用方法,以抑制Menin与MLL1、MLL2和MLL融合癌基因蛋白的相互作用(例如,用于治疗白血病、实体肿瘤和其他依赖于MLL1、MLL2、MLL融合蛋白和/或Menin活性的疾病)。
  • COMPOSITIONS COMPRISING THIENOPYRIMIDINE AND THIENOPYRIDINE COMPOUNDS AND METHODS OF USE THEREOF
    申请人:THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    公开号:US20160046647A1
    公开(公告)日:2016-02-18
    The present invention relates generally to thienopyrimidine and thienopyridine class compounds and methods of use thereof. In particular embodiments, the present invention provides compositions comprising thienopyrimidine and thienopyridine class compounds and methods of use to inhibit the interaction of menin with MLL1, MLL2 and MLL-fusion oncoproteins (e.g., for the treatment of leukemia, solid cancers and other diseases dependent on activity of MLL1, MLL2, MLL fusion proteins, and/or menin).
    本发明涉及噻吩嘧啶和噻吩啶类化合物及其使用方法。在特定实施例中,本发明提供包含噻吩嘧啶和噻吩啶类化合物的组合物以及使用方法,以抑制Menin与MLL1、MLL2和MLL融合癌蛋白的相互作用(例如,用于治疗依赖于MLL1、MLL2、MLL融合蛋白和/或Menin活性的白血病、实体癌和其他疾病)。
  • METHODS AND COMPOSITIONS FOR INHIBITING THE INTERACTION OF MENIN WITH MLL PROTEINS
    申请人:Kura Oncology, Inc.
    公开号:EP4006030A2
    公开(公告)日:2022-06-01
    The present disclosure provides compositions and methods of use to inhibit the interaction of menin with MLL1, MLL2 and MLL-fusion oncoproteins. The compositions and methods of use are useful for the treatment of leukemia, solid cancers, diabetes and other diseases dependent on activity of MLL1, MLL2, MLL fusion proteins, and/or menin.
    本公开提供了抑制 menin 与 MLL1、MLL2 和 MLL 融合肿瘤蛋白相互作用的组合物和使用方法。这些组合物和使用方法可用于治疗白血病、实体癌、糖尿病和其他依赖于 MLL1、MLL2、MLL 融合蛋白和/或 menin 活性的疾病。
  • Methods and compositions for inhibiting the interaction of menin with MLL proteins
    申请人:Kura Oncology, Inc.
    公开号:US10174041B2
    公开(公告)日:2019-01-08
    The present disclosure provides compositions and methods of use to inhibit the interaction of menin with MLL1, MLL2 and MLL-fusion oncoproteins. The compositions and methods of use are useful for the treatment of leukemia, solid cancers, diabetes and other diseases dependent on activity of MLL1, MLL2, MLL fusion proteins, and/or menin.
    本公开提供了抑制 menin 与 MLL1、MLL2 和 MLL 融合肿瘤蛋白相互作用的组合物和使用方法。这些组合物和使用方法可用于治疗白血病、实体癌、糖尿病和其他依赖于 MLL1、MLL2、MLL 融合蛋白和/或 menin 活性的疾病。
查看更多